New TP53 MASTR

New TP53 MASTR

Molecular Biology

September 29, 2015

Multiplicom is pleased to announce the release of the TP53 MASTR molecular assay, research use only, for the identification of mutations in the entire coding region of TP53.

TP53 is the most frequently mutated gene in cancer and is associated with Li-Fraumeni syndrome, an inherited cancer syndrome. The TP53 MASTR is designed for intended use both on germline material as well as FFPE material.
NGS-based analysis of TP53 mutations has a wide variety of clinical and research applications.

Germline mutation detection

  • for cancer predisposition testing (e.g. Li-Fraumeni syndrome)

Somatic mutation detection

  • for molecular tumor classification and as prognostic biomarker (including leukemia (e.g. CLL, Non-Hodgekin lymphoma), sarcomas, bladder and esophageal cancer)
  • for prediction of therapeutic success (e.g. TP53-targeting drugs and MDM2 inhibitors)
  • for clonality analysis to discriminate primary tumors and metastases

 

The TP53 MASTR has several advantages:

  • clear clinical guidelines to use the test
  • compatible with DNA derived from both FFPE tumor samples and blood

SOMATIC 2 MASTR Plus and QC Plex Product Release

SOMATIC 2 MASTR Plus and QC Plex Product Release

Molecular Biology

Multiplicom is pleased to introduce the SOMATIC 2 MASTR™ Plus, a research use only assay, for sequencing analysis of genes involved in pathways of solid tumors formation. The SOMATIC 2 MASTR Plus is provided as a ready to use assay in three multiplex PCR reactions for the identification of mutations in the complete coding regions of the EGFR, ERBB2, PIK3CA, PIK3R1 and PTEN genes.

March 24, 2015 More +
Studying Hypoxia?

Studying Hypoxia?

Molecular Biology

There is more to hypoxia than just HIF-1 alpha activation. Find some of its downstream targets and which tools are available to study them.

 

 

January 03, 2017 More +
Ready to make an enquiry Call us on: + 961 1 39 66 77
Or email us